Pharmacology, Efficacy and Safety of a Triple-Secured Fibrinogen Concentrate in Children Less than or Equal to 12 Years with Afibrinogenaemia

Khayat C. D., El Khorassani M., Aytac Ş. S., Harroche A., Dahmane A., Pujol S., ...More

THROMBOSIS AND HAEMOSTASIS, vol.120, no.6, pp.957-967, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 120 Issue: 6
  • Publication Date: 2020
  • Doi Number: 10.1055/s-0040-1710015
  • Journal Name: THROMBOSIS AND HAEMOSTASIS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.957-967
  • Hacettepe University Affiliated: Yes

Abstract

Objective To date, the use of a fibrinogen concentrate (FC) administered in children with inherited fibrinogen deficiency is poorly documented. Treatment modalities may differ from those of adults. The aim of this study was to investigate the pharmacokinetics (PK), efficacy (bleeding/surgery) and safety of a triple-secured FC (FibCLOT, LFB, France) in young patients aged of 12 years or less.